Open-label study of bevacizumab (Avastin®) plus taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer

Update Il y a 4 ans
Reference: EUCTR2006-002529-21

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to assess the safety profile of bevacizumab when combined with taxane monotherapy or in combination as first line treatment of patients with locally recurrent (LR) or metastatic breast cancer (mBC).


Inclusion criteria

  • Locally Recurrent or Metastatic Breast Cancer